A Phase III Clinical Study of Valsartan Oral Solution for the Treatment of Hypertension in Children and Adolescents
Phase 3
- Conditions
- Essential Hypertension
- Interventions
- Drug: Valsartan Oral SolutionDrug: Placebo
- First Posted Date
- 2025-03-07
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Shandong New Time Pharmaceutical Co., LTD
- Target Recruit Count
- 342
- Registration Number
- NCT06863987
- Locations
- 🇨🇳
Shandong New Time Pharmaceutical Co.LTD,, Linyi, Shandong, China
Phase III Clinical Study of Cetirizine Hydrochloride Injection in Treatment of Acute Urticaria
Phase 3
Recruiting
- Conditions
- Acute Urticaria
- Interventions
- Drug: Cetirizine Hydrochloride InjectionDrug: Diphenhydramine Hydrochloride Injection
- First Posted Date
- 2025-02-11
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Shandong New Time Pharmaceutical Co., LTD
- Target Recruit Count
- 284
- Registration Number
- NCT06819774
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, BeiJing, Beijing, China
Phase II Clinical Study of Vonorasan Fumarate Injection in the Treatment of Peptic Ulcer Bleeding
Phase 2
Not yet recruiting
- Conditions
- Peptic Ulcer Bleeding
- Interventions
- Drug: Vonorasan fumarate injection1Drug: Vonorasan fumarate injection2
- First Posted Date
- 2025-01-20
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Shandong New Time Pharmaceutical Co., LTD
- Target Recruit Count
- 150
- Registration Number
- NCT06783257
A Phase Ⅱ Study of Mosapride Citrate Injection in the Treatment of Postoperative Gastrointestinal Dysfunction
Phase 2
Recruiting
- Conditions
- Postoperative Gastrointestinal Dysfunction
- Interventions
- Drug: Mosapride Citrate Injection(low)Drug: Mosapride Citrate Injection(high)Drug: Placebo
- First Posted Date
- 2025-01-20
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Shandong New Time Pharmaceutical Co., LTD
- Target Recruit Count
- 150
- Registration Number
- NCT06782594
- Locations
- 🇨🇳
Shandong New Time Pharmaceutical Co., LTD, Feixian, Shandong, China
🇨🇳Tongji Hospital Affiliated to Tongji Medical College Hust, Wuhan, China
A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer
Phase 2
- Conditions
- Cervical Cancer
- Interventions
- First Posted Date
- 2025-01-01
- Last Posted Date
- 2025-01-01
- Lead Sponsor
- Shandong New Time Pharmaceutical Co., LTD
- Target Recruit Count
- 510
- Registration Number
- NCT06755515
- Locations
- 🇨🇳
Shandong New Time Pharmaceutical Co., LTD, Linyi, Shandong, China
A Phase I Study OfLNF2007 Monotherapy in Patients with Advanced Solid Tumors
- First Posted Date
- 2024-12-30
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Shandong New Time Pharmaceutical Co., LTD
- Target Recruit Count
- 94
- Registration Number
- NCT06752447
Phase II Clinical Study of AC591 in Preventing Oxaliplatin-Induced Peripheral Neuropathy
Phase 2
Not yet recruiting
- Conditions
- Colorectal Adenoma
- Interventions
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Shandong New Time Pharmaceutical Co., LTD
- Target Recruit Count
- 120
- Registration Number
- NCT06722950
A Phase Ⅱ Study of F520 in Patients With Cervical Carcinoma
Phase 2
Completed
- Conditions
- Cervical Cancer
- Interventions
- Drug: Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- Shandong New Time Pharmaceutical Co., LTD
- Target Recruit Count
- 29
- Registration Number
- NCT06226350
- Locations
- 🇨🇳
Shandong New Time Pharmaceutical Co., LTD, Shandong, China
Phase I Study of LNF1901 in Advanced Malignant Tumors
Phase 1
Not yet recruiting
- Conditions
- Advanced Malignant Tumors
- Interventions
- Drug: LNF1901 Monoclonal Antibody Injection
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- Shandong New Time Pharmaceutical Co., LTD
- Target Recruit Count
- 82
- Registration Number
- NCT06226363
Phase I Study of XZ120 in Malignant Tumors
Phase 1
Not yet recruiting
- Conditions
- Advanced Malignancies
- Interventions
- Drug: XZ120 injection
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Shandong New Time Pharmaceutical Co., LTD
- Target Recruit Count
- 123
- Registration Number
- NCT06206915
© Copyright 2025. All Rights Reserved by MedPath